Food and Drug Regulations, C.R.C., c. 870

Section C.05.015

Cite as Food and Drug Regulations, C.R.C., c. 870, s. C.05.015 · current to June 17, 2026 · regulation last amended June 17, 2026

Statute Watch

Get an alert when a bill in Parliament would change this section, and every time it moves.

The text

(1) If a clinical trial is discontinued by the sponsor in its entirety or at a clinical trial site, the sponsor shall (a) inform the Minister no later than 15 days after the date of the discontinuance; (b) provide the Minister with the reason for the discontinuance and its impact on the proposed or ongoing clinical trials in respect of the drug conducted in Canada by the sponsor; (c) as soon as possible, inform all qualified investigators of the discontinuance and of the reasons for the discontinuance, and advise them in writing of any potential risks to the health of clinical trial subjects or other persons; and (d) in respect of each discontinued clinical trial site, stop the sale or importation of the drug as of the date of the discontinuance and take all reasonable measures to ensure the recovery of all unused quantities of the drug that have been sold. (2) If the sponsor has discontinued the clinical trial in its entirety or at a clinical trial site, the sponsor may resume selling or importing the drug for the purposes of a clinical trial in its entirety or at a clinical trial site if, in respect of each clinical trial site where the sale or importation is to be resumed, the sponsor submits to the Minister the information referred to in subparagraphs C.05.005(c)(ix) and (x) and paragraphs C.05.005(d) and (h).
Read the Food and Drug Regulations on the Justice Laws Website ↗

Made under Food and Drugs Act, R.S.C. 1985, c. F-27.

Bills in Parliament that would change this section 0

No bill we hold would amend or repeal this section.